/
: Overview: We are a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Our beta islet, T cell and NK cell programs are allogeneic, meaning they are derived from healthy donors for use in any patient, rather than being sourced from a…
The business is unprofitable at the operating level (-15.82% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 1556.8% YoY with margins expanding 2080.7pp.
Negative free cash flow of -$105M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$109M
▲ +1556.8% YoY
Net Income (TTM)
-$108M
▲ +92.4% YoY
Op. Margin
-15.82%
▲ +2080.7pp YoY
ROIC
-36.46%
▲ +42.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$95M
▲ +5.0% YoY
Op. Cash Flow (TTM)
-$95M
▲ +5.7% YoY
Net Debt
-$87M
Net Cash Position
Cash & Equiv.
$135M
3Y CAGR: +175.9%
Continue Research